"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.
| Descriptor ID |
D000071449
|
| MeSH Number(s) |
D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
|
| Concept/Terms |
Proprotein Convertase 9- Proprotein Convertase 9
- Convertase 9, Proprotein
- Neural Apoptosis-Regulated Convertase 1
- Neural Apoptosis Regulated Convertase 1
- NARC-1 Protein
- NARC 1 Protein
- Proprotein Convertase, Subtilisin-Kexin Type 9
- Proprotein Convertase, Subtilisin Kexin Type 9
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".
This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.
-
Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. J Am Heart Assoc. 2022 02; 11(3):e023328.
-
Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022 03 02; 30(3):1343-1351.
-
Watts JK, Ockene IS. RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease. Nucleic Acid Ther. 2020 02; 30(1):1-3.
-
Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, Cao Y, Gallant J, Xue W, Rivera-P?rez JA, Sontheimer EJ. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In?Vivo Genome Editing. Mol Cell. 2019 Feb 21; 73(4):714-726.e4.
-
Ibraheim R, Song CQ, Mir A, Amrani N, Xue W, Sontheimer EJ. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018 09 19; 19(1):137.
-
Ochin CC, Garelnabi M. Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells. Cardiovasc Hematol Disord Drug Targets. 2018; 18(1):61-70.
-
Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017 Dec; 35(12):1179-1187.